Zota Health Care Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹4,585 Cr
- ROE
- -15.00%
- Price to sales
- 7.53
- Debt to equity
- 0.39
- 52W high / low
- ₹1,687 / ₹1,028
- Sales growth (5Y)
- 38.38%
- EBITDA margin
- 0.49%
- Net profit margin
- -12.80%
- Promoter holding
- 49.38%
- Sales (last year)
- ₹609 Cr
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
Guidance scorecard · Q2 FY27 call
What Zota Health Care Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
- Aggressive store expansion planned from Q3 and Q4 FY27, with around 650 store additions targeted for the full year.
- Mature stores (850+ stores) contribute significantly to profitability, offsetting new store expansion impact.
- Stores typically reach maturity within 12-18 months, with mature stores generating INR4.13 lakh+ GMV/month.
- Same-store sales growth (SSG) remains strong, with some cohorts showing 30%+ annualized growth.
- The company expects to become fully cash positive by end of Q4 FY27 or Q1 FY28.
- Marketing initiatives and brand-building expected to drive demand and penetration, supporting revenue growth.
2 more points from Zota Health Care Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Zota Health Care Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Zota Health Care Limited made strategic investments in SKIA and UGO Generics, investing INR 2 crores each; both are in early stages with pilot rollouts beginning and expected progress from next quarter onward.
- The company acquired Globotask IT Consultancy to strengthen internal IT capabilities, enhance data security, reduce reliance on external IT vendors, and achieve cost benefits long-term.
- However, store expansion continues with planned addition of 600-650 stores in the current financial year, indicating ongoing investment in retail footprint and operations.
- Emphasis on brand building and marketing investments, including brand ambassadors, suggests continued strategic capital allocation toward marketing rather than heavy physical asset investments.
FundraisingQ1 FY27 call
See what Zota Health Care Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Zota Health Care Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Zota Health Care Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Zota Health Care Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Zota Health Care Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 66.15% | 66.15% | 64.44% | 62.40% | 62.02% | 59.72% | 57.42% | 55.81% | 50.64% | 49.38% | 49.38% | 49.38% |
| FIIs + | 0.00% | 0.00% | 0.01% | 0.01% | 0.24% | 0.87% | 3.82% | 3.49% | 8.09% | 8.21% | 7.92% | 6.92% |
| DIIs + | 0.00% | 0.00% | 0.00% | 0.99% | 1.03% | 3.08% | 4.25% | 4.95% | 7.22% | 6.40% | 6.75% | 7.30% |
| Public + | 33.85% | 33.85% | 35.55% | 36.60% | 36.71% | 36.33% | 34.52% | 35.75% | 34.06% | 36.00% | 35.96% | 36.40% |
| No. of Shareholders | 7,589 | 7,435 | 7,661 | 8,937 | 9,763 | 10,389 | 10,354 | 11,855 | 13,185 | 14,005 | 14,678 | 14,928 |
Financials of Zota Health Care Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 | 143 | 163 | 174 | 199 |
| Expenses + | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 | 143 | 154 | 185 | 196 |
| Operating Profit | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 | 6 | -0 | 9 | -12 | 3 |
| OPM % | 10% | 7% | -3.0% | -2.2% | -1.3% | -8% | 2.5% | 3.8% | 4.9% | -0.3% | 5% | -7% | 1.5% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | -3 | 2 | 5 |
| Interest | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 | 5 | 5 | 6 | 6 |
| Depreciation | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 | 22 | 27 | 28 | 29 |
| Profit before tax | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 | -14 | -26 | -26 | -44 | -27 |
| Tax % | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% | 13% | 14% | -45% | 1% | -4% |
| Net Profit + | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 | -16 | -30 | -14 | -44 | -26 |
| EPS in Rs | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.50 | -4.81 | -5.20 | -8.73 | -4.09 | -12.58 | -7.39 |
Financials of Zota Health Care Ltd
Profit & Loss
Annual income statement trend
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 538 | 679 |
| Expenses + | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 520 | 679 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | 19 | -0 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 4.8% | 0.6% | 11% | 5% | 4.2% | -2.0% | 3.4% | -0.0% |
| Other Income + | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 6 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 17 | 23 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 82 | 106 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -58 | -80 | -123 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | -7% | |
| Net Profit + | 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -57 | -74 | -114 |
| EPS in Rs | 1.00 | 0.99 | 1.54 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.70 | -21.35 | -32.79 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% | -5% | -5% |
Financials of Zota Health Care Ltd
Balance Sheet
Capital structure and asset base
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 35 | 35 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 | 659 | 591 |
| Borrowings + | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 | 270 | 271 |
| Other Liabilities + | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 | 167 | 197 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 1,131 | 1,094 |
| Fixed Assets + | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 | 369 | 382 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 15 | 5 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 | 264 | 168 |
| Other Assets + | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 | 483 | 538 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 1,131 | 1,094 |
Financials of Zota Health Care Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 3 | 5 | -3 | 6 | -1 | 13 | -2 | -6 | -50 | -82 | ||
| Cash from Investing Activity + | -1 | -1 | 9 | -4 | 4 | -27 | 15 | -13 | -92 | -330 | ||
| Cash from Financing Activity + | -2 | -4 | -6 | -3 | -2 | 14 | -14 | 19 | 145 | 503 | ||
| Net Cash Flow | 0 | 0 | -1 | -1 | 1 | 1 | -1 | -0 | 3 | 92 | ||
| Free Cash Flow | 2 | 4 | -6 | -1 | -2 | 10 | -13 | -23 | -96 | -208 | ||
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 78% | 81% | -12% | 147% | -134% | 115% | 2% | -59% | 811% | -380% |
Financials of Zota Health Care Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 | 51 | 50 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 | 277 | 324 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 | 111 | 176 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 | 217 | 198 |
| Working Capital Days | 102 | 70 | 78 | 80 | 175 | 152 | 143 | 108 | 111 | 75 | 100 | 84 |
| ROCE % | 20% | 32% | 6% | -2% | 15% | -2% | -7% | -17% | -8% |
Guidance history
How Zota Health Care Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q4 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 20–40% | Up 2%+ | Planned | Planned | — |
| Q2 FY26 call → | 20–40% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
27 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −14.9% | 43% |
| Last 6 months | +0.9% | 55% |
| Last 3 months | +8.0% | 77% |
The price is 21.5% below its all-time high of ₹1,687 (15 Dec 2025). Stocks more than 20% below their peak have their score halved, so 54 became 27.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Zota Health Care Ltd: 0.4 × 43 + 0.4 × 55 + 0.2 × 77 = 54, halved to 27 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Zota Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY